🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

The sexually transmitted infection are escalating around the world, with data suggesting over 82 million infections annually. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the reality of rising global incidence, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Outcomes and Global Access

Based on data published in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which involves a dual-drug approach. The research involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in many low-income and middle-income countries.

Clinicians treating patients have voiced optimism. The availability of a easy-to-administer therapy like this is hailed as a "game-changer" for public health efforts. This is considered vital to alleviate the strain of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea globally.